877291-09-3

Upstream product

• 877291-15-1 13-cyclohexyl-3-methoxy-7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid, dimethyl ester 
• 494799-18-7 methyl 3-cyclohexyl-1H-indole-6-carboxylate 
• 494799-17-6 3-cyclohexyl-1-methyl-1H-indole-6-carboxylic acid 
• 494799-16-5 3-(cyclohex-1-en-1-yl)-1H-indole-6-carboxylic acid 
• 494799-19-8 methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate 
• 1670-82-2 Indole-6-carboxylic acid 
• 50820-65-0 indole-6-carboxylic acid methyl ester 
• 902147-82-4 methyl 11-cyclohexyl-6-hydroxy-8-methoxy-6H-isoindolo[2,1-a]indole-3-carboxylate 
• 108-94-1 cyclohexanone 

Downstream Products

• 929632-60-0 C₃₁H₃₆N₂O₆ 
• 929630-74-0 methyl 13-cyclohexyl-3-(methyloxy)-6-(((5-(methyloxy)-2,5-dioxopentyl)amino)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate 

Relevant academic research and scientific papers

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

INHIBITORS OF HCV REPLICATION

Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of

Indolobenzazepine HCV NS5B inhibitors

The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.